Legacy Financial Advisors Inc. Lowers Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Legacy Financial Advisors Inc. cut its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 10.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 22,620 shares of the company’s stock after selling 2,713 shares during the quarter. Legacy Financial Advisors Inc.’s holdings in Takeda Pharmaceutical were worth $293,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in TAK. Principal Securities Inc. bought a new position in shares of Takeda Pharmaceutical in the fourth quarter worth approximately $28,000. Wells Fargo & Company MN boosted its holdings in Takeda Pharmaceutical by 1.7% in the 4th quarter. Wells Fargo & Company MN now owns 774,552 shares of the company’s stock worth $11,053,000 after buying an additional 12,756 shares during the period. Aigen Investment Management LP purchased a new stake in Takeda Pharmaceutical in the 4th quarter worth $197,000. Catalytic Wealth RIA LLC bought a new stake in Takeda Pharmaceutical during the fourth quarter valued at about $233,000. Finally, Gold Investment Management Ltd. purchased a new position in shares of Takeda Pharmaceutical in the fourth quarter valued at about $994,000. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Stock Performance

NYSE TAK opened at $14.80 on Friday. The business has a 50-day moving average price of $14.32 and a 200-day moving average price of $13.76. The firm has a market cap of $47.09 billion, a price-to-earnings ratio of 26.91, a price-to-earnings-growth ratio of 0.27 and a beta of 0.54. Takeda Pharmaceutical Company Limited has a twelve month low of $12.57 and a twelve month high of $16.06. The company has a quick ratio of 0.74, a current ratio of 1.26 and a debt-to-equity ratio of 0.65.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. Takeda Pharmaceutical had a net margin of 6.02% and a return on equity of 10.11%. The business had revenue of $7.75 billion during the quarter. As a group, equities research analysts predict that Takeda Pharmaceutical Company Limited will post 1.63 EPS for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.